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Objective: The objective of this study was to build a model to differentiate between borderline and
invasive ovarian tumors.
Materials and Methods: We performed a retrospective study involving 148 patients with borderline or
invasive ovarian tumors in our institute between 1997 and 2012. Clinical and pathologic data were
collected. Logistic regression was used to build the model.
Results: The model was created based on the following variables (p < 0.05): menopausal status; pre-
operative serum level of cancer antigen 125; the greatest diameter of the tumor; and the presence of
solid parts on ultrasound imaging. The sensitivity and speciﬁcity of the model were 94.6% [95% conﬁ-
dence interval (CI), 0.887e1] and 78.3% (95% CI, 0.614e0.952) for patients aged  50 years, and 76.0%
(95% CI, 0.622e0.903) and 60.0% (95% CI, 0.438e0.762) for those aged < 50 years, respectively. The
performance of the model was tested using cross-validation.
Conclusion: Differentiation between borderline and invasive ovarian tumors can be achieved using a
model based on the following criteria: menopausal status; cancer antigen 125 level; and ultrasound
parameters. The model is helpful to oncologists and patients in the initial evaluation phase of ovarian
tumors.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Ovarian cancer is the second leading cause of death in women's
gynecological cancers worldwide, and the leading cause to death in
developed countries [1]. Women with an ovarian mass often pre-
sent a diagnostic challenge to physicians because benign, invasive,
and low malignant potential tumors (borderline ovarian tumor:
BOT) require different surgical interventions. Many attempts have
been made to distinguish malignant tumors from benign tumors
[2e5], however, little effort has been focused on differentiating
BOTs from invasive tumors.ohsiung 813, Taiwan.
hiang).
bstetrics & Gynecology. PublishedIt is often difﬁcult for gynecologic oncologists to establish a
diagnosis of a BOT prior to surgery. Many patients with BOTs pre-
sent characteristics similar to invasive tumors, such as the presence
of solid components and ascites on ultrasound imaging, and
elevated serum levels of tumor markers, such as cancer antigen
(CA)125 [6]. However, unlike invasive tumors, BOTs typically occur
in young women with an intention to preserve fertility, and they
have a favorable prognosis, even after conservative treatment [7,8].
Therefore, it is desirable to differentiate BOTs from invasive tumors
preoperatively to avoid unnecessary procedures. A risk calculator
with a good predictive value before surgery would be of great help
to oncologists and patients.
The standard diagnostic procedures for patients with ovarian
masses include ultrasound imaging and blood tests of tumorby Elsevier Taiwan LLC. All rights reserved.
Table 1
Distribution of patients' surgical and pathological information.
Borderline Invasive
Age (y), median (range) 46.5 (14e85) 52.0 (26e77)
Number of patients
< 50 y 35 (60.3) 34 (37.8)
 50 y 23 (39.7) 56 (62.2)
Histological type
Serous 16 (27.6) 28 (31.1)
Mucinous 38 (65.5) 7 (7.8)
Endometrioid 1 (1.7) 26 (28.9)
Mixed 1 (1.7) 8 (8.9)
Clear cell 0 15 (16.7)
Other a 2 (3.5) 6 (6.6)
FIGO Stage
IA 9 (10.0)
IB 51 (88) 2 (2.2)
IC 15 (16.8)
IIB 0 2 (2.2)
IIC 3 (5.2) 8 (8.9)
IIIA 2 (3.4) 3 (3.3)
IIIB 0 2 (2.2)
IIIC 2 (3.4) 37 (41.1)
IV 0 10 (11.1)
Unknown 0 2 (2.2)
Frozen section analysis
Benign 2 (3.4) 0
Borderline 53 (91.4) 2 (2.2)
Invasive 0 81 (90)
Not performed 3 (5.2) b 7 (7.8) c
Overall
148 58 90
Data are presented as n (%) unless otherwise indicated.
FIGO ¼ International Federation of Gynecology and Obstetrics.
a Brenner tumor, undifferentiated, and unknown types.
b Frozen section analysis was not performed due to seemingly benign tumors in
surgery.
c Frozen section analysis was not performed because these patients were
admitted to our institute for restaging surgery based on their pathology reports
from their local hospitals.
Table 2
Univariate analysis of patients' characteristics.
p Standard error
Body mass index 0.63 0.04
Gravida 0.82 0.09
CEA 0.48 0.41
CA19-9 0.11 0.54
CA125 <0.001 0.39
Tumor size 0.001 0.03
Solid parts 0.03 0.34
Ascites 0.01 0.38
Septa 0.003 0.36
The cut off values of CEA, CA199, and CA125 are 5.0 ng/mL, 37.0 U/mL, and 80 U/mL,
respectively. The tumor size denotes the longest tumor diameter in preoperative
ultrasound imaging. The presence of solid parts, ascites, and septa was based on
ﬁndings in the preoperative ultrasound imaging.
CA ¼ cancer antigen; CEA ¼ carcinoembryonic antigen.
J. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 398e402 399markers, such as CA125, carcinoembryonic antigen, and CA19-9.
There have also been reports on adjunctive examinations, such as
positron emission tomography, computed tomography, magnetic
resonance imaging, and new tumor markers, such as calprotectin,
oviduct-speciﬁc glycoprotein 1, growth differentiation factor 15,
human epididymis protein 4, and a new diagnostic multivariate
index assay, the OVA1 test [6,9,10]. Although these tests may help
detect invasive tumors, they have not been shown to play a sig-
niﬁcant role in diagnosing BOTs. In addition, in many parts of the
worldwheremedical costs are amajor concern, adjunctive tests are
only performed when malignancy is suspected after initial testing,
or not performed at all due to high medical costs or limited medical
resources. We therefore developed a model based on the results of
initial testing (ultrasonographic ﬁndings and tumor markers) to
evaluate the probability of a BOT versus an invasive ovarian tumor.
Materials and methods
This retrospective study was conducted at the Kaohsiung Vet-
erans' General Hospital (KSVGH), a public teaching medical center
in south Taiwan. All patient information was retrieved from the
hospital records, including electronic and chart data. The acquisi-
tion of data was approved by the institutional review board of
KSVGH. Information was retrieved from 148 patients, who had
pathologic reports of epithelial borderline or invasive ovarian tu-
mors between May 1997 and January 2012 at KSVGH. Of the 148
patients, 58 had BOTs. Two senior pathologists were consulted on
the cases and reviewed the pathology slides following the World
Health Organization criteria for the diagnosis of BOTs [11]. It was
agreed that all 58 patients had BOTs. The ultrasound reports of all
the patients were reviewed by three physicians from the KSVGH
Department of Obstetrics and Gynecology to ensure accuracy.
All statistical analyses were conducted using the statistical
computing and graphic drawing language, R [12]. Patients who
were aged < 50 years and those who were aged  50 years were
divided into two separate regression curves. The patients were
grouped according to age because not all of them reported their
menopause status. We chose 50 years of age to represent the
menopause because the median age of menopause amongst Chi-
nese women in Taiwan is 50 years [13] and 50e51.4 years for
women in Europe and North America [14].
Cross-validationwas performed to check the performance of the
model. The data were randomly partitioned into two sets in each
age group, with one set comprised of only one patient. The model
was trained based on the larger data set, and it was then applied to
the single-patient set to test whether or not malignancy was
correctly predicted. The same procedure was performed in rota-
tions for all of the patients, and the results were averaged out over
all of the rounds.
Results
The current study included 148 patients; 58 patients had BOTs
and 90 patients had invasive cancer. Most patients with BOTs were
aged < 50 years (60.3%) and had mucinous histology (65.5%). The
majority of the patients with invasive cancer were aged  50 years
(62.2%), and serous histology was most common (31.1%). The ma-
jority of patients underwent intraoperative frozen section analysis
(94.8% for BOTs and 92.2% for invasive tumors). The demographics
of the patients are shown in Table 1.
To identify the factors that differentiate BOTs from invasive tu-
mors, we ﬁrst performed univariate analysis with logistic regres-
sion to test a series of parameters, including body mass index,
gravida, preoperative serum levels of CA125, carcinoembryonic
antigen and CA19-9, the greatest tumor diameter, and the presenceof ascites, solid parts, and septa on preoperative ultrasound imag-
ing (Table 2). We then performed multivariate analysis on those
factors with p < 0.05 (Table 3). The preoperative serum level of
CA125, the greatest tumor diameter, and the presence of solid parts
were signiﬁcant factors (p < 0.05) based on multivariate analysis
(Tables 2 and 3). The factors were then used to derive the following
formulas:
Aged < 50 years:
R¼1.23þ 1.57 [CA125(80)] 0.004 sizeþ 0.57 [solid part]
Table 3
Multivariate analysis of patients' characteristics.
p Standard error
CA125 <0.001 0.70
Tumor size 0.03 0.05
Solid parts 0.002 0.64
Ascites 0.18 0.64
Septa 0.43 0.64
The cut off value of CA125 is 80 U/mL. The tumor size denotes the longest tumor
diameter in preoperative ultrasound imaging. The presence of solid parts, ascites,
and septa was based on ﬁndings in the preoperative ultrasound imaging.
CA ¼ cancer antigen.
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R ¼ 0.54 þ 4.53  [CA125(80)]  0.25  size þ 2.69  [solid part]
Pre- and postmenopausal patients were ﬁtted into two separate
regression curves because the same factor may have different
weights according to menopausal status [2e4].
CA125 is assigned 1 if the level is 80 U/mL, and 0 if <80 U/mL.
An abnormal level of CA125 is >35 U/mL [15], however, different
cut-off values, ranging from 10 U/mL to 200 U/mL, have been used
in managing ovarian tumors [2,16]. In our work, we found that a
CA125 cut-off level of 80 U/mLwasmost powerful in discriminating
BOTs from invasive ovarian tumors. Size (in cm) refers to the
greatest tumor diameter on ultrasound imaging. Solid parts is
assigned 1 if present on ultrasound imaging, and 0 if not present. A
positive result or zero (R  0) predicted an invasive tumor, and a
negative R predicted a BOT.
The preoperative CA125 level had a profound effect on the
prediction. For patients aged < 50 years, if the CA125 level was
>80 U/mL, the hazard ratio of an invasive tumor versus a BOT was
4.78; for patients aged  50 years, the hazard ratio was 92. The
presence of solid parts increased the odds of getting an invasive
tumor by 77% for the younger group (aged < 50 years), and 13 times
for older patients (aged 50 years). By contrast, tumor size slightly
decreased the probability of an invasive tumor. For every 1 cm in-
crease in tumor diameter, the probability of an invasive ovarian
tumor decreased by 0.4% for patients aged < 50 years and 28% for
those who were aged  50 years.
The model we created had a sensitivity of 94.6% [95% conﬁdence
interval (CI), 0.887e1; 53/56 tumors were correctly predicted as
invasive] and a speciﬁcity of 78.3% (95% CI, 0.614e0.952,18/21 were
correctly predicted as BOTs) for patients whowere aged 50 years.
The positive and negative predictive values for this group were
91.0% and 85.7%, respectively. For patients aged < 50 years, the
sensitivity was 76.0% (95% CI, 0.622e0.903, 26/34 were correctly
predicted as invasive), and the speciﬁcity was 60.0% (95% CIe
0.438e0.762, 21/35 were correctly predicted as BOTs). The positiveTable 4
Model performance in predicting invasive tumors from borderline ovarian tumors (BOTs
Menopausal status Disease Predicted BOT Predicted invasive
Combined BOT 39 19
Invasive 11 79
Total 50 98
Aged < 50 y BOT 21 14
Invasive 8 26
Total 29 40
CV
Aged  50 y BOT 18 5
Invasive 3 53
Total 21 58
CV
CV ¼ cross validation; NPV ¼ negative predictive value; PPV ¼ positive predictive valueand negative predictive values were 65.0% and 72.4%, respectively.
These results are summarized in Table 4, and the receiver operating
characteristic curve analysis is shown in Figure 1.
To further test the value of the model, cross-validation was
performed. Cross-validation is a rotation process to assess how a
statistical model generalizes to apply to independent data [17]. The
sensitivity was 94.6% (95% CI, 0.887e1) and the speciﬁcity was
69.6% (95% CI, 0.508e0.884) for the group aged  50 years, and the
sensitivity was 74.4% (95% CI, 0.622e0.907) and the speciﬁcity was
60.0% (95% CI, 0.438e0.762) for the other group (Table 4).
Compared with the sensitivities and speciﬁcities before cross-
validation, the sensitivities and speciﬁcities were the same or
slightly lower, which suggests that the model is reliable in dis-
tinguishing BOTs from invasive ovarian tumors and can be applied
to independent data.
Discussion
BOTs have long been a diagnostic challenge to gynecologic on-
cologists because they often exhibit similar behaviors to invasive
carcinomas [18]. In contrast to invasive carcinomas, BOTs usually
have an excellent prognosis. In addition, a signiﬁcant percentage of
patients are still of reproductive age, and conservative treatment,
including a unilateral salpingo-oophorectomy or a cystectomy for
Stage I BOTs, is often preferred to preserve future fertility [7,19].
Radical surgery, which consists of peritoneal washings, a total
abdominal hysterectomy, bilateral salpingo-oophorectomy, infra-
colic omentectomy, complete peritoneal resection of macroscopic
lesions, or multiple peritoneal biopsies, is recommended for pa-
tients at advanced stage or those who are ﬁnished with repro-
duction [20]. It is therefore important to prepare patients and
oncologists for the tumor type with reasonable certainty before
surgery. Indeed, the risk model we developed will contribute
signiﬁcantly to the preoperative diagnosis.
Only a few previous studies have focused on differentiating
BOTs from invasive tumors. Zanetta et al [21] proposed a model in
1995 to differentiate BOTs based on complex sonographic intra-
cystic features, and reported a 91% accuracy. Similarly, a recent
study by Sobiczewski et al [16] developed a scoring system that
included six ultrasonographic parameters (e.g., echogenicity) to
distinguish BOTs from invasive cancers, and they had a sensitivity
of 90.2%. Compared with these studies, our model considered a
much larger patient pool; speciﬁcally, we had 148 patients,
including 58 BOTs, whereas in the aforementioned studies, only 20
BOTs and 16 BOTs were enrolled, respectively. Our model is also
simpler and based on fewer parameters with a similar sensitivity.
A noteworthy feature of our study was that we tested the model
performance using cross-validation, which assesses how accurate a
model is when applied to independent data [17]. A good model).
Total Sensitivity Speciﬁcity PPV NPV
58 87.8% 67.2% 80.6% 78.0%
90
148
35 76.5% 60.0% 65.0% 72.4%
34
69
76.5% 60.0%
23 94.6% 78.3% 91.0% 85.7%
56
78
94.6% 69.6%
.
Figure 1. Receiver operating characteristic curve analysis of risk prediction in
assessment of borderline and invasive ovarian tumors. The area under the curve was
0.667 for patients aged < 50 years and 0.953 for patients aged  50 years.
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sensitivity or speciﬁcity, which was achieved in our study (Table 3),
suggesting that our model had stable performance and may work
well with independent data. It would be of great interest to test it
with a large sample of external data which relies on patient infor-
mation from other institutions.
Ultrasonography is currently the most popular imaging
approach in clinical practice to evaluate ovarian masses, due to its
wide accessibility and low cost. Detailed sonographic ﬁndings, such
as wall and septal thicknesses, and Doppler parameters, such as
pulsatility index (PI) and resistive index (RI) values and velocimetry
ﬂow evaluation, have been reported in patients with BOTs [22e24].
According to these studies, no speciﬁc parameters could typically
differentiate BOTs from invasive tumors. Aside from the diagnostic
limitations, medical costs are also a concern. State-of-the-art im-
aging techniques are more costly, and they are usually ordered after
an ultrasound image suggestive of malignancy. In areaswith limited
medical resources, new technical advances may not be widely
accessible in the near future. We therefore based our study on
grayscale sonographic parameters, hoping to provide a riskmodel in
the very early stage of evaluationwithout referring to complex tests.
It should be noted that the majority of the BOT patients in this
study had a mucinous tumor (65.5%). Mucinous BOTs have been
reported to be predominant in Asia, whereas serous BOTs are pre-
dominant in the USA and Europe [25]. This may partially explain
why a larger tumor size lowered the risk of an invasive tumor in the
model we developed, because mucinous tumors are usually bigger.
Another possible reason is that most BOTs are diagnosed at an early
stage, whereas most invasive tumors are diagnosed at a late stage. A
recent study hypothesized that early-stage tumors grow locally and
advanced-stage tumors disseminate while still small [26]. If this
holds true, early-stage BOTs may grow to a large size before
detection.
It should also be noted that we achieved very high sensitivity
and speciﬁcity in the older group (aged  50 years). It seems more
complicated and difﬁcult to differentiate BOTs and invasive tumors
in women at a childbearing age, and more advanced diagnostic
procedures may have to be used to improve detection of BOTs.In conclusion, we have developed a model to predict the risk of
BOTs or invasive ovarian tumors early during the preoperative
evaluation. The model has a potential wide application, particularly
in areas with limited medical resources and in areas with a pre-
dominance of mucinous BOTs, such as Asia. Further studies should
be directed to validate our model prospectively in an external and
heterogeneous population.
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